论文部分内容阅读
目的:探讨复方胃宁片联合三联疗法治疗幽门螺杆菌(HP)感染慢性胃炎患者的临床疗效及安全评价。方法:90例幽门螺杆菌感染慢性胃炎患者随机分成两组,治疗组予以复方胃宁片、雷贝拉唑钠肠溶片、阿莫西林克拉维酸钾干混悬剂、克拉霉素缓释片,2次/天,14天后续予复方胃宁片,2次/天,服用14天;对照组予以枸橼酸铋钾、雷贝拉唑钠肠溶片、阿莫西林克拉维酸钾干混悬剂、克拉霉素缓释片,2次/天,服用14天,采用快速尿素酶试验和13C-尿素呼气试验(13C-UBT)检测患病和根治情况。结果:治疗组和对照组幽门螺杆菌根除率分别为75.56%、80.00%,差异无统计学意义(P<0.05);治疗组嗳气、腹胀症状改善情况好于对照组(P<0.05),治疗组出现1例不良反应并退出治疗,对照组出现2例不良反应并退出治疗。结论:复方胃宁片联合三联疗法治疗幽门螺杆菌(HP)感染慢性胃炎疗效与对照组相近,但治疗组改善症状明显,不良反应少。
Objective: To investigate the clinical efficacy and safety evaluation of Fufang Weining Tablet combined with triple therapy in the treatment of Helicobacter pylori (HP) infection in patients with chronic gastritis. Methods: 90 cases of Helicobacter pylori infection in chronic gastritis patients were randomly divided into two groups, the treatment group to be Fu Weining tablets, rabeprazole sodium enteric-coated tablets, amoxicillin and clavulanate potassium dry suspension, clarithromycin slow release Tablets, 2 times / day, 14 days after the continued Fufang Weining tablets, 2 times / day, taking 14 days; the control group to bismuth citrate, rabeprazole sodium enteric-coated tablets, amoxicillin potassium clavulanate Dry suspension, clarithromycin sustained-release tablets, 2 times / day, taking 14 days, rapid urease test and 13C-urea breath test (13C-UBT) detection of disease and cure. Results: The eradication rates of Helicobacter pylori in the treatment group and control group were 75.56% and 80.00%, respectively, with no significant difference (P <0.05). The improvement of asthma and bloating symptom in the treatment group was better than that in the control group (P <0.05) One case of adverse reactions occurred in the group and quit treatment, two cases of adverse reactions in the control group and withdrawal from treatment. Conclusion: The therapeutic effect of Fufang Weining Tablet combined with triple therapy on chronic gastritis with Helicobacter pylori (HP) infection is similar to that of the control group. However, the treatment group has obvious symptoms and few adverse reactions.